Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2

Moomoo News · Sep 25 14:32 · Ratings

Maxim Group analyst Jason McCarthy maintains $Brainstorm Cell Therapeutics (BCLI.US)$ with a buy rating, and maintains the target price at $2.

According to TipRanks data, the analyst has a success rate of 24.4% and a total average return of -21.9% over the past year.

AnalystRecentRatingAutoNews_210432_20240924_022bceaade95f1a10cce590d93ddef26eacc7b25_1727289066339603_mm_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2

Risk Disclaimer